Kraig Biocraft Laboratories Successfully Completes Recombinant Cocoon Production From Spring Trials
ANN ARBOR, Mich., April 22, 2024 (GLOBE NEWSWIRE) — Kraig Biocraft Laboratories, Inc. (OTCQB:KBLB) (“the Company” or “Kraig Labs”), announces today what it considers to be a major milestone. The Company has completed rearing of the first generation of its new BAM-1 parental strains as part of its spring production trial. Kraig Labs has successfully produced cocoon at rates that exceeded all expectations and control parameters for these trials.
Related news for (KBLB)
- From Spider Silk to Biotech and Power Meets Precision Across Infrastructure, Energy, and Transport
- Worms, Lasers, and Donuts
- Biotech, Ballistics, Blockchain & Battlespace Tech Dominate Today’s Market Narrative
- Kraig Labs Scalable Spider Silk May Unlock the Future of Lightweight Body Armor and Ballistic Protection
- Biotech Breakthroughs, Trans Snack Surges & a Spider Silk Revolution Power Small-Cap Rally
